Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 5,272 matching trials from the live ClinicalTrials.gov search.
Filters: Gainesville, Florida Clear all
Terminated No phase listed Observational

Connect® Myeloid Disease Registry

NCT01688011
View directory record Official record
Conditions
Primary Myelofibrosis, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
Interventions
Luspatercept
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
2,013 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
155
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 131 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

NCT01224171
View directory record Official record
Conditions
Crohn's Disease
Interventions
vedolizumab, Placebo
Drug · Other
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
40
States / cities
Lafayette, Colorado • Hamden, Connecticut • Gainesville, Florida + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 30, 2026, 4:15 PM EDT
Active, not recruiting No phase listed Observational

A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

NCT04158934
View directory record Official record
Conditions
Hemophilia A
Interventions
ADYNOVI/ADYNOVATE
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Not listed
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 30, 2026, 4:15 PM EDT
Terminated Phase 2 Interventional

Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery

NCT00628264
View directory record Official record
Conditions
Cardiac Surgery, Coronary Artery Bypass Grafting, Valve Surgery, Kidney Injury
Interventions
AP214, Placebo
Drug
Lead sponsor
Action Pharma A/S
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 1, 2009 · Synced Oct 30, 2026, 4:15 PM EDT
No Longer Available No phase listed Expanded access

Single-Patient Expanded Access Protocol - RNA-LP in a Patient With Recurrent Osteosarcoma

NCT07560709
View directory record Official record
Conditions
Recurrent Osteosarcoma
Interventions
pp65/tumor mRNA RNA-LP
Biological
Lead sponsor
University of Florida
Other
Eligibility
15 Years to 17 Years · Male only
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Not applicable Interventional

IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction

NCT01226563
View directory record Official record
Conditions
Acute Myocardial Infarction, Congestive Heart Failure, ST-Elevation Myocardial Infarction
Interventions
IK-5001, Saline Solution
Device
Lead sponsor
Bellerophon BCM LLC
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
16
States / cities
Birmingham, Alabama • Torrance, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

NCT05624606
View directory record Official record
Conditions
Influenza Immunization
Interventions
Quadrivalent Influenza mRNA Vaccine MRT5410, Quadrivalent Recombinant Influenza vaccine RIV4, Quadrivalent Inactivated Influenza Standard Dose QIV-SD, Quadrivalent Inactivated Influenza High Dose QIV-HD
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
23
States / cities
Huntington Park, California • Long Beach, California • North Hollywood, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

StrataGraft® Skin Tissue Expanded Access at Specific Study Sites ( StrataCAT )

NCT04123548
View directory record Official record
Conditions
Deep Partial-thickness Burn
Interventions
StrataGraft skin tissue
Biological
Lead sponsor
Stratatech, a Mallinckrodt Company
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Orange, California • Washington D.C., District of Columbia • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Spinal Excitation to Enhance Mobility

NCT03667573
View directory record Official record
Conditions
Aging
Interventions
tsDCS Dosage (A), tsDCS Dosage (B), textured shoe insoles
Device · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Tocilizumab (TCZ) in New-onset Type 1 Diabetes

NCT02293837
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, New-onset Type 1 Diabetes Mellitus, T1DM, T1D
Interventions
Tocilizumab (TCZ), Placebo, Standard of Care
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 17 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
17
States / cities
San Francisco, California • Stanford, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

NCT01081145
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Extended-release Guanfacine Hydrochloride, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
27
States / cities
Dothan, Alabama • Little Rock, Arkansas • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

Cleft Palate Surgery and Speech Development

NCT00004639
View directory record Official record
Conditions
Cleft Lip, Cleft Palate
Interventions
Furlow double z-plasty palatoplasty palate repair, Von Langenbeck palatoplasty palate repair
Procedure
Lead sponsor
University of Florida
Other
Eligibility
Not listed
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Oct 30, 2026, 4:15 PM EDT
Active, not recruiting Not applicable Interventional

A Behavioral mHealth Intervention for People With HIV With Anxiety and Depression

NCT07112001
View directory record Official record
Conditions
HIV, Depression, Anxiety
Interventions
PositiveLinks with Counseling, Standard of Care (SOC)
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Phase 4 Interventional Results available

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

NCT01842581
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis
Interventions
Rifaximin, Lactulose
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
43
States / cities
Phoenix, Arizona • Coronado, California • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 30, 2026, 4:15 PM EDT
No Longer Available No phase listed Expanded access

A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation

NCT00149981
View directory record Official record
Conditions
Organ Transplantation
Interventions
everolimus (RAD)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
68
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 51 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation

NCT03513328
View directory record Official record
Conditions
Bone Marrow Failure Syndrome, Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Acquired Neutropenia in Newborn, Acquired Anemia Hemolytic, Acquired Thrombocytopenia, Hemophagocytic Lymphohistiocytoses, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, Common Variable Immunodeficiency, X-linked Lymphoproliferative Disease, Severe Combined Immunodeficiency, Hurler Syndrome, Mannosidosis, Adrenoleukodystrophy
Interventions
Thiotepa--single daily dose, Thiotepa--escalated dose
Drug
Lead sponsor
University of Florida
Other
Eligibility
3 Months to 39 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy

NCT02607800
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF/VEL/VOX, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
47
States / cities
Long Beach, California • Los Angeles, California • Palo Alto, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Nutritional Supplement, Eccentric Exercise and Recovery

NCT01444170
View directory record Official record
Conditions
Injury, Inflammation
Interventions
dicreatinol sulfate, placebo sugar pill
Dietary Supplement · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 25 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 30, 2026, 4:15 PM EDT
Terminated Phase 3 Interventional

Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome

NCT02179151
View directory record Official record
Conditions
Prader-Willi Syndrome, Obesity
Interventions
ZGN-440 for Injectable Suspension, ZGN-440 Placebo for Injectable Suspension
Drug
Lead sponsor
Zafgen, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
15
States / cities
Sacramento, California • San Diego, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228

NCT00106301
View directory record Official record
Conditions
Carcinoma, Renal Cell, Prostatic Neoplasms
Interventions
FK228 (romidepsin)
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
4
States / cities
Duarte, California • Gainesville, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

NCT02927262
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
Interventions
Gilteritinib, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
6
States / cities
Gainesville, Florida • Jacksonville, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 30, 2026, 4:15 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

NCT05738486
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
Interventions
Donanemab, Placebo, Dexamethasone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
43
States / cities
Chandler, Arizona • Irvine, California • Long Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Phase 3 Interventional

Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period

NCT03714373
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
DCCR, Placebo for DCCR
Drug
Lead sponsor
Soleno Therapeutics, Inc.
Industry
Eligibility
4 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
20
States / cities
Orange, California • Palo Alto, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Not applicable Interventional Results available

Tourette Syndrome Deep Brain Stimulation

NCT02056873
View directory record Official record
Conditions
Tourette Syndrome
Interventions
Continuous DBS, Responsive Brain Stimulation (RBS Setting)
Device
Lead sponsor
University of Florida
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 30, 2026, 4:15 PM EDT